{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:05:34Z","timestamp":1738645534382,"version":"3.35.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102163","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T06:20:59Z","timestamp":1721456459000},"page":"102163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2144-6469","authenticated-orcid":false,"given":"Deniz","family":"Tural","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3783-7432","authenticated-orcid":false,"given":"Cagatay","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer Fatih","family":"Olmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102163_bib0001","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.euo.2018.05.011","article-title":"From Clinical trials to real-life clinical practice: the role of immunotherapy with pd-1\/pd-l1 inhibitors in advanced urothelial carcinoma","volume":"1","author":"Hussain","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102163_bib0002","first-page":"00256","article-title":"Five-Year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: experience from real-world clinical practice","volume":"7673","author":"Tural","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102163_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102163_bib0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2217\/imt-2021-0220","article-title":"Complete response and survival outcomes in patients with advanced cancer on immune checkpoint inhibitors","volume":"14","author":"Kartolo","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.clgc.2024.102163_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejca.2017.09.018","article-title":"Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomized prospective studies","volume":"86","author":"Roviello","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.clgc.2024.102163_bib0006","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102163_bib0007","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102163_bib0008","first-page":"16","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"495","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.clgc.2024.102163_bib0009","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","article-title":"Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I\/II trial with paclitaxel, cisplatin, and gemcitabine","volume":"95","author":"Bellmunt","year":"2002","journal-title":"Cancer"},{"issue":"7_suppl","key":"10.1016\/j.clgc.2024.102163_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/jco.2011.29.7_suppl.238","article-title":"Defining \"cisplatin ineligible\" patients with metastatic bladder cancer","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl_5","key":"10.1016\/j.clgc.2024.102163_bib0011","first-page":"S678","article-title":"Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1). Poster presented at ESMO","volume":"32","author":"Rosenberg","year":"2021","journal-title":"Abstract 699P. Ann. Oncol."},{"key":"10.1016\/j.clgc.2024.102163_bib0012","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.euf.2020.10.009","article-title":"Partial response and stable disease correlate with positive outcomes in atezolizumab-treated patients with advanced urinary tract arcinoma","volume":"7","author":"Bedke","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2024.102163_bib0013","doi-asserted-by":"crossref","first-page":"602.e1","DOI":"10.1016\/j.urolonc.2020.02.005","article-title":"The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients","volume":"38","author":"Ogihara","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102163_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10147-020-01784-w","article-title":"Prognostic value of pre-treatment risk stratification and post-treatment neutrophil\/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma","volume":"26","author":"Yamamoto","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102163_bib0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/cas.14762","article-title":"Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab","volume":"112","author":"Kobayashi","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2024.102163_bib0016","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.21873\/anticanres.13539","article-title":"Initial experience of pembrolizumab therapy in japanese patients with metastatic urothelial cancer","volume":"39","author":"Yasuoka","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2024.102163_bib0017","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1007\/s10147-021-01936-6","article-title":"Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab","volume":"26","author":"Tural","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102163_bib0018","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10147-021-02072-x","article-title":"Response to first-line chemotherapy regimen is associated with efficacy of \u0131mmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma","volume":"27","author":"Tural","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102163_bib0019","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.euf.2020.09.010","article-title":"Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: results of real-life experiences","volume":"7","author":"Tural","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2024.102163_bib0020","doi-asserted-by":"crossref","first-page":"5151e7","DOI":"10.1158\/0008-5472.CAN-12-0733","article-title":"Why RECIST works and why it should stay: counterpoint","volume":"72","author":"Fojo","year":"2012","journal-title":"Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324001344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T06:57:18Z","timestamp":1738565838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324001344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324001344"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102163","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102163","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102163"}}